Skip to content
Governance Register

← US public companies

Lyell Immunopharma, Inc.

SEC CIK 1806952 · LYEL · last insider filing 2026-06-18

Directors (from insider filings)

NameCapacity as filedFilings
Seely Lynn Director · President and CEO filed 2021 - 2026
Rieflin William JL Director filed 2021 - 2026
Brawley Otis W Director filed 2021 - 2026
Friedman Cathy Director filed 2021 - 2026
Ramachandra Sumant Director filed 2024 - 2026
Klausner Richard Director · Executive Chairman filed 2021 - 2026
Nabel Elizabeth G Director filed 2021 - 2026
Bachleda Mark Director filed 2025 - 2026
Nelsen Robert Director filed 2021 - 2026
Bishop Hans Edgar Director filed 2021 - 2024
Homans Elizabeth Director · Chief Executive Officer filed 2021 - 2022

Officers (from insider filings)

NameTitle as filedFilings
Hill Stephen J. Chief Technical Ops. Officer filed 2021 - 2026
Lee Gary K. Chief Scientific Officer filed 2022 - 2026
Bulis Veronica Sanchez VP, Corporate Controller filed 2025 - 2026
Shook David Chief Medical Officer filed 2025 - 2026
Shah Smital Chief Fin. and Bus. Officer filed 2026 - 2026
Meltz Mark A General Counsel filed 2025 - 2026
Newton Charles W. Chief Financial Officer filed 2021 - 2025
Lang Matthew Chief Business Officer filed 2023 - 2025
Thompson Rahsaan Chief Legal Officer filed 2022 - 2023
Albertson Tina M. Chief Medical Officer filed 2022 - 2023
Turner Heather D Chief General Counsel filed 2021 - 2022

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.